Evidence map›Paper›PMID 32188842›Full record

ArticleCell death & disease2020

Nonenzymatic function of Aldolase A downregulates miR-145 to promote the Oct4/DUSP4/TRAF4 axis and the acquisition of lung cancer stemness.

Yu-Chan Chang, Yi-Fang Yang, Jean Chiou, Hsing-Fang Tsai, Chih-Yeu Fang, Chih-Jen Yang, Chi-Long Chen, Michael Hsiao

Open access · goldAbstract read
In one paragraph

Article in Cell death & disease, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
1.4field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 36 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Yu-Chan Chang *Genomics Research Center, Academia Sinica, Taipei, 115, Taiwan.ORCID http://orcid.org/0000-0003-0474-9935
Yi-Fang Yang *Department of Medical Education and Research, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan.
Jean ChiouGenomics Research Center, Academia Sinica, Taipei, 115, Taiwan.
Hsing-Fang TsaiGenomics Research Center, Academia Sinica, Taipei, 115, Taiwan.
Chih-Yeu FangGenomics Research Center, Academia Sinica, Taipei, 115, Taiwan.
Chih-Jen YangDepartment of Internal Medicine, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.
Chi-Long ChenDepartment of Pathology, Taipei Medical University Hospital, Taipei Medical University, Taipei, 110, Taiwan. chencl@tmu.edu.tw.
Michael HsiaoGenomics Research Center, Academia Sinica, Taipei, 115, Taiwan. mhsiao@gate.sinica.edu.tw.ORCID http://orcid.org/0000-0001-8529-9213
Genomics Research Center, Academia Sinica · TWKaohsiung Medical University · TWKaohsiung Veterans General Hospital · TWTaipei Medical University Hospital · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Drug resistance remains a serious issue of clinical importance and is a consequence of cancer stemness. In this study, we showed that the level of Aldolase A (ALDOA) expression is significantly associated with the IC50 value of chemotherapy drugs in lung cancer. Our data revealed that ALDOA overexpression resulted in a significant increase of lung tumor spheres. The use of ingenuity pathway analysis (IPA) resulted in the identification of POU5F1 (Oct4) as the leading transcription factor of ALDOA. We observed high expression of ALDOA, Oct4 and stemness markers in collected spheroid cells. DUSP4 and TRAF4 were confirmed as major downstream targets of the ALDOA-Oct4 axis. Knockdown of these molecules significantly decreased the stemness ability of cells. In addition, we investigated whether miR-145 targets the 3'-UTR of Oct4 and is regulated by ALDOA due to the involvement of ALDOA in glycolysis and metabolic reprogramming. Furthermore, we constructed several mutant forms of ALDOA that disrupted its enzymatic activity and showed that they still induced significant in vitro sphere formation and in vivo tumorigenicity. These results demonstrated that ALDOA-mediated spheroid formation is independent of its enzymatic activity. In the clinical component, we also showed that the combination of ALDOA and TRAF4 or DUSP4 is positively correlated with poor overall survival in a xenograft model and cancer patients through immunohistochemical analyses. The results of our study revealed novel functional roles of ALDOA in inducing cancer stemness via the inhibition of miR-145 expression and the activation of Oct4 transcription. These findings offer new therapeutic strategies for modulation of lung cancer stemness to enhance chemotherapeutic responses in lung cancer patients.

Indexed as

AnimalsCell Line, TumorCell ProliferationDown-RegulationDual-Specificity PhosphatasesFructose-Bisphosphate AldolaseHeterograftsHumansLung NeoplasmsMaleMiceMice, Inbred NODMice, SCIDMicroRNAsMitogen-Activated Protein Kinase PhosphatasesNeoplastic Stem CellsALDOA protein, humanDual-Specificity PhosphatasesDUSP4 protein, humanFructose-Bisphosphate AldolaseMicroRNAsMIRN145 microRNA, humanMitogen-Activated Protein Kinase PhosphatasesOctamer Transcription Factor-3POU5F1 protein, humanTNF Receptor-Associated Factor 4TRAF4 protein, human

Identifiers

PMID32188842
PMCPMC7080828
OpenAlexW3012501026

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.